Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile RSPO3 over exp
Therapy N/A
Indication/Tumor Type cancer
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RSPO3 over exp cancer not applicable N/A Preclinical - Pdx & cell culture Emerging In a preclinical study, advanced solid tumor cells overexpressing Rspo3 in culture and in patient-derived xenograft models demonstrated inhibition of beta-catenin activity and suppression of tumor growth when treated with RSPO3 specific antibodies, suggesting RSPO3 may be a promising therapeutic target (PMID: 26719531). 26719531
PubMed Id Reference Title Details
(26719531) Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types. Full reference...